Compare Eli Lilly And Co (LLY) vs Marriott International Inc (MAR) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Marriott International (MAR) trades at $365.88, up 2.63% with strong technical momentum and bullish moving averages. The company shows solid revenue growth to $26.19B in 2025 and consistent earnings beats, though valuation ratios remain elevated with a P/E of 37.38. Recent developments include strategic technology partnerships and dividend declarations, while institutional activity shows mixed positioning adjustments.

Outlook remains positive with analyst consensus target of $386.71 offering 5.7% upside potential. Key opportunities include travel recovery momentum and operational efficiency gains, while risks center on high debt levels (debt-to-asset ratio of 58.83%) and potential economic sensitivity. The stock presents a balanced risk-reward profile with moderate growth expectations.